ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0382

Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability

Gregory McDermott1, Faith Selzer1, Sizheng Zhao2, Joerg Ermann3 and Jeffrey Katz1, 1Brigham and Women's Hospital, Boston, MA, 2University of Manchester, Liverpool, United Kingdom, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Access to care, socioeconomic factors, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with axial spondyloarthritis (axSpA) experience significant delay between symptom onset and diagnosis. Determinants of delay are incompletely understood. We investigated the associations between demographic, medical and socioeconomic factors and axSpA diagnostic delay.

Methods: We identified patients with axSpA diagnosed by rheumatologists in a large, multihospital healthcare system between December 1990 and October 2021. We used a published electronic health record (EHR) screening algorithm and medical record review to select patients who met modified New York criteria for ankylosing spondylitis (AS) or 2009 ASAS classification criteria for axSpA. Diagnostic delay was determined based on the duration of back pain that patients reported at diagnosis. We reviewed the EHR to determine specialty care and disease manifestations at or prior to diagnosis. We mapped patient addresses to US census tract and determined their social vulnerability index (SVI) by referencing the 2018 US Centers for Disease Control SVI Atlas. SVI is an area-level composite measure of poverty, lack of access to transportation, crowded housing and household income. Consistent with prior research, we considered patients in the 80-99th SVI percentiles nationally to have the highest level of vulnerability. We categorized duration of delay (0-1, 1-4, or >4 years) and investigated differences between groups using Kruskal-Wallis and chi-squared tests. We examined the association between disease manifestations and SVI on diagnostic delay using ordinal logistic regression adjusted for demographic and clinical factors.

Results: We included 555 patients with new axSpA diagnosis in our healthcare system. The mean diagnostic delay was 6.8 +8.5 years (median 3.8). Groups with longer delay were younger at symptom onset (median age 29 vs 31 vs 37 years in the >4 years, 1-4 years and 0-1 year delay groups, respectively). Those with >4 years of delay were more likely to seek ophthalmology care for uveitis prior to diagnosis (27% vs 12%, Table 1). In multivariable ordinal logistic regression analyses, AS at diagnosis (OR 2.42, 95%CI 1.69-3.48) and uveitis history (OR 2.43, 95%CI 1.50-4.02) were associated with longer diagnostic delay. HLA-B27 positivity (OR 0.68, 95%CI 0.47-0.997), peripheral arthritis (OR 0.68, 95%CI 0.47-0.99) and older age at symptom onset (OR 0.80, 95%CI 0.75-0.86 per 5 years) were associated with shorter delay. The 80-99th percentile of SVI was associated with longer diagnostic delay (OR 1.96, 95%CI 1.04-3.84) after adjustment for demographic and clinical factors (Table 3).

Conclusion: We identified several clinical and socioeconomic factors that may influence diagnostic delay in axSpA. Older age at back pain onset, peripheral arthritis and positive HLA-B27 were associated with shorter delay. In contrast to other disease manifestations, uveitis was more common among patients with >4 years of diagnostic delay and nearly one third of this group sought ophthalmology care prior to diagnosis. Patients with higher socioeconomic vulnerability had longer diagnostic delay independent of clinical factors. These findings may help identify education and screening strategies to facilitate timely axSpA diagnosis.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. McDermott, None; F. Selzer, None; S. Zhao, UCB; J. Ermann, Novartis, Pfizer, AbbVie/Abbott, UCB, Eli Lilly; J. Katz, Biosplice.

To cite this abstract in AMA style:

McDermott G, Selzer F, Zhao S, Ermann J, Katz J. Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-diagnostic-delay-in-axial-spondyloarthritis-impact-of-clinical-factors-and-social-vulnerability/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-diagnostic-delay-in-axial-spondyloarthritis-impact-of-clinical-factors-and-social-vulnerability/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology